TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35412495

Group type: EXPERIMENTAL
Intervention: Intensive hydration (IH) with Ringer's Lactate at a rate of 3 mL/kg/h during and for 8 h following the procedure, plus an additional bolus of 20 mL/kg at the end of the procedure.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard hydration (SH) with Ringer's Lactate at a rate of 1.5 mL/kg/h during and for 8 h following the procedure.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Intensive hydration (IH) with Ringer's Lactate.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard hydration (SH) with Ringer's Lactate.
Number of subjects: 155
Study: 33485746

Group type: EXPERIMENTAL
Intervention: Buzzy® (n = 36)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR; n = 37)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Distraction Cards (DC; n = 35)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (n = 34)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Buzzy®
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Distraction Cards (DC)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study: 32860041

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months (ACS)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) combined with a P2Y12 inhibitor and aspirin 100 mg for 1-12 months (ACS)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months (CCS)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) combined with a P2Y12 inhibitor and aspirin 100 mg for 1-12 months (CCS)
Number of subjects: 751
Study: 35347756

Group type: EXPERIMENTAL
Intervention: Generalized weighted combination test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stage 1 data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stage 2 data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data example
Number of subjects: 0
Study: 33650980

Group type: EXPERIMENTAL
Intervention: Web-based mindfulness program
Number of subjects: 19
Study: 33972458

Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Combined Approach (SR+CA)
Number of subjects: 2643

Group type: COMPARATOR
Intervention: Stent Retriever (SR)
Number of subjects: 2643
Study: 34742029

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-BFR training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (BFR and non-BFR)
Number of subjects: 35
Study: 35909888

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillatory expectoration system (HFCWO)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 65
Study: 33298127

Group type: EXPERIMENTAL
Intervention: Blended online and human behavioural therapy for tics
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Digital technology for trial procedures
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Highly trained and motivated trial staff
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison with 51 trials conducted between 2010 and 2020
Number of subjects: 51
Study: 35972369

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 176
Study: 33326316

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRPT vaccine (administered as a 6, 10, 14 week primary series with a toddler booster at 15-18 months)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRPT vaccine
Number of subjects: 64
Study: 32352494

Group type: EXPERIMENTAL
Intervention: Genetically assessed MSE refractive error (per-unit increase in D)
Number of subjects: 405692

Group type: EXPERIMENTAL
Intervention: 6-D decrease in MSE refractive error
Number of subjects: 405692

Group type: EXPERIMENTAL
Intervention: Genetically assessed IOP (per-unit increase in mm Hg)
Number of subjects: 405692
Study: 616475925

Group type: EXPERIMENTAL
Intervention: Furosemide (160 mg i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg p.o.) plus Furosemide
Number of subjects: 10
Study: 35749512

Group type: EXPERIMENTAL
Intervention: Kinesthetic motor-imagery training (KMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static visual imagery training (SVI)
Number of subjects: 0
Study: 32703720

Group type: EXPERIMENTAL
Intervention: Vitamin D oral pill (100,000 IU)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Skin oil application (SOA) plus vitamin D3 suspension with essential oil enhancer
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (pill, oral liquid, SOA)
Number of subjects: 62
Study: 32879767

Group type: EXPERIMENTAL
Intervention: DIMS spectacle lenses (n = 79)
Number of subjects: 160

Group type: COMPARATOR
Intervention: SV spectacle lenses (n = 81)
Number of subjects: 160
Study: 34773606

Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg once daily
Number of subjects: 5734

Group type: EXPERIMENTAL
Intervention: Finerenone 20 mg once daily
Number of subjects: 5734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study: 32379637

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation training for 6 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: No rehabilitation intervention (Control)
Number of subjects: 72
Study: 33753428

Group type: EXPERIMENTAL
Intervention: DuoPACT (structured six-session couples counselling intervention)
Number of subjects: 300

Group type: COMPARATOR
Intervention: LifeSteps (three-session individually-delivered HIV adherence counselling intervention)
Number of subjects: 300
Study: 34623638

Group type: EXPERIMENTAL
Intervention: VAC (vincristine, dactinomycin, and cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VAC/VI (VAC alternating with vincristine plus irinotecan)
Number of subjects: 0
Study: 34347815

Group type: EXPERIMENTAL
Intervention: Daytime noise pollution levels measured in dBA (Leq, 5-min)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Noise land-use regression model
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Validation model of noise land-use regression
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Community per capita income
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Predicted daytime noise levels
Number of subjects: 75
Study: 33217785

Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73 m2
Number of subjects: 1334
Study: 32114889

Group type: EXPERIMENTAL
Intervention: Evolocumab (Q2W dose)
Number of subjects: 7690

Group type: EXPERIMENTAL
Intervention: Evolocumab (monthly dose)
Number of subjects: 7690

Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 7690
Study: 33814182

Group type: EXPERIMENTAL
Intervention: Phenol treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical treatment (excision and primary closure)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 34028808

Group type: EXPERIMENTAL
Intervention: 2% simvastatin/2% cholesterol cream applied twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bland emollients
Number of subjects: 8
Study: 32569854

Group type: EXPERIMENTAL
Intervention: Active imagery rescripting (ImRs-A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Passive imagery rescripting (ImRs-P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imagery rehearsal (IRE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-intervention control (NIC)
Number of subjects: 100
Study: 35583280

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C with chemotherapy
Number of subjects: 0
Study: 34221603

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 30
Study: 33337797

Group type: EXPERIMENTAL
Intervention: MgSO4-rocuronium
Number of subjects: 280

Group type: COMPARATOR
Intervention: Saline-succinylcholine
Number of subjects: 280
Study: 34542059

Group type: EXPERIMENTAL
Intervention: Monopolar PRF
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bipolar PRF
Number of subjects: 66
Study: 32720988

Group type: EXPERIMENTAL
Intervention: Chikungunya virus-like particle vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35459183

Group type: EXPERIMENTAL
Intervention: Patient-centred post-stroke hospital/home transition programme combining telephonic support by a trained case manager and access to an interactive Internet information platform for 12 months.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Patient-centred post-stroke hospital/home transition programme.
Number of subjects: 170
Study: 33980233

Group type: EXPERIMENTAL
Intervention: Antenatal care use
Number of subjects: 3727

Group type: EXPERIMENTAL
Intervention: Delivery care use
Number of subjects: 3727

Group type: EXPERIMENTAL
Intervention: Postnatal care use
Number of subjects: 3727
Study: 36018222

Group type: EXPERIMENTAL
Intervention: Time-averaged cumulative blood pressure (cumBP)
Number of subjects: 3330

Group type: COMPARATOR
Intervention: Spironolactone treatment
Number of subjects: 3330
Study: 34338714

Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride, 20 mg daily for 26 weeks
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1221
Study: 35131634

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 21
Study: 33837906

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (500 mL) plus standard drugs
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 62
Study: 34482499

Group type: EXPERIMENTAL
Intervention: Religious Coping Scale
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Positive Religious Coping subscale
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Negative Religious Coping subscale
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Negative religious coping in male adolescents aged 15-17
Number of subjects: 514
Study: 34042299

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal eating (NE)
Number of subjects: 21
Study: 35202009

Group type: EXPERIMENTAL
Intervention: Wheat bran fiber (WBF) and probiotic Bifidobacterium animalis subsp. lactis GCL2505 (PB GCL2505)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-volume regimen (1.0 to 1.5 L of MoviPrep)
Number of subjects: 40
Study: 32539588

Group type: EXPERIMENTAL
Intervention: Pause reading intervention
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dialogic reading intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Active shared reading control condition
Number of subjects: 150
Study: 35162319

Group type: COMPARATOR
Intervention: Not specified; the study is a cross-sectional survey and part of a phase III wait-listed cluster randomised controlled trial.
Number of subjects: 0
Study: 33225724

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) - four individual face-to-face sessions per month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no motivational interviewing)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 60
Study: 33523688

Group type: EXPERIMENTAL
Intervention: Social Selection (described as 'friends')
Number of subjects: 280

Group type: COMPARATOR
Intervention: Object Selection (described as 'toys')
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Social Selection of a numerically rare group
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Social Selection with active selection of friends
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Social Selection of a rare selected group
Number of subjects: 280
Study: 35084374

Group type: EXPERIMENTAL
Intervention: Distress from palpitations
Number of subjects: 293
Study: 33293672

Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 37143013

Group type: EXPERIMENTAL
Intervention: Physical activity counseling intervention (PACINPAT)
Number of subjects: 95
Study: 32985122

Group type: EXPERIMENTAL
Intervention: ABC/3TC/DTG
Number of subjects: 91

Group type: COMPARATOR
Intervention: TDF/FTC/NNRTI
Number of subjects: 91
Study: 32928717

Group type: EXPERIMENTAL
Intervention: Supraflex Cruz stent
Number of subjects: 1550

Group type: COMPARATOR
Intervention: SYNERGY stent
Number of subjects: 1550
Study: 34515056

Group type: EXPERIMENTAL
Intervention: 20% human albumin solution (HAS)
Number of subjects: 1508

Group type: COMPARATOR
Intervention: 4% human albumin solution (HAS)
Number of subjects: 1508
Study: 33078978

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Doxorubicin 45 mg/m2 and cisplatin 50 mg/m2 (day 1), followed by paclitaxel 160 mg/m2 (day 2) with granulocyte colony-stimulating factor
Number of subjects: 1381
Study: 34975146

Group type: EXPERIMENTAL
Intervention: Exenatide extended release once-weekly (ExQW)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 36258233

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 37
Study: 34190361

Group type: EXPERIMENTAL
Intervention: romosozumab 210 mg monthly for 12 months
Number of subjects: 4093

Group type: COMPARATOR
Intervention: alendronate 70 mg weekly for 12 months
Number of subjects: 4093
Study: 36173985

Group type: EXPERIMENTAL
Intervention: EGD with CO2 insufflation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pre-EGD AUS
Number of subjects: 30
Study: 34610729

Group type: EXPERIMENTAL
Intervention: Creatine supplementation immediately before resistance training
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Creatine supplementation immediately after resistance training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo immediately before resistance training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo immediately after resistance training
Number of subjects: 10
Study: 32379269

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) daily for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35514277

Group type: EXPERIMENTAL
Intervention: Exercises with a Pilates ball (IG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 62
Study: 33353735

Group type: COMPARATOR
Intervention: Flowable SFRC as luting-core material with individually-made FRC post (Group C3)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Packable SFRC (Group C1)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Other groups (A1-A2, B1-B2, C2, C4)
Number of subjects: 170
Study: 34557093

Group type: EXPERIMENTAL
Intervention: Interdisciplinary physician-pharmacist medication review
Number of subjects: 93
Study: 32023233

Group type: EXPERIMENTAL
Intervention: Bicruciate-retaining TKA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cruciate-retaining TKA
Number of subjects: 50
Study: 36333791

Group type: EXPERIMENTAL
Intervention: Mobilizing to toilet
Number of subjects: 116

Group type: COMPARATOR
Intervention: Bedpan use
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mobilizing to toilet after crossover
Number of subjects: 116

Group type: COMPARATOR
Intervention: Bedpan use after crossover
Number of subjects: 116
Study: 33667870

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) 150 mg/kg, ad libitum feeding
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) 150 mg/kg, pair-fed
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) free-fed
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP) ad libitum feeding
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 378
Study: 32490838

Group type: EXPERIMENTAL
Intervention: SMART‐COPD intervention (n=19)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 30
Study: 36055582

Group type: EXPERIMENTAL
Intervention: Recruitment and retention strategies
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Retention at 3 months
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Retention at 6 months (primary endpoint)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Retention at 12 months (follow-up)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Retention differences by gender or race/ethnicity
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Retention differences by recruitment method
Number of subjects: 382
Study: 34185442

Group type: EXPERIMENTAL
Intervention: Periodontal status
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Number of teeth
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES)
Number of subjects: 303
Study: 36348460

Group type: EXPERIMENTAL
Intervention: Stage 1 outline applications
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Stage 2 full applications
Number of subjects: 95
Study: 33203399

Group type: EXPERIMENTAL
Intervention: docetaxel-sunitinib
Number of subjects: 68

Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 68
Study: 36181096

Group type: EXPERIMENTAL
Intervention: Teach-back method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study: 32885909

Group type: EXPERIMENTAL
Intervention: Maternal lifestyle intervention
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 277

Group type: COMPARATOR
Intervention: Attention control (home safety)
Number of subjects: 277
Study: 35715661

Group type: EXPERIMENTAL
Intervention: Oversight arm
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-oversight arm
Number of subjects: 140
Study: 34509801

Group type: EXPERIMENTAL
Intervention: safinamide 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: safinamide 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: safinamide 50 mg and 100 mg
Number of subjects: 0
Study: 32132009

Group type: EXPERIMENTAL
Intervention: Telephonic diabetes self-management intervention (Bronx A1C)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Print-only (PrO) control arm
Number of subjects: 816
Study: 35973188

Group type: EXPERIMENTAL
Intervention: Freshwater fish-based diet (F group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Freshwater fish-based and red meat-based diet alternately (F/M group)
Number of subjects: 34
Study: 33683991

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32065514

Group type: EXPERIMENTAL
Intervention: PF-05221304 (1-240 mg single doses or 2-200 mg daily repeated doses for 14 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PF-05221304 (repeated doses)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PF-05221304 (doses yielding ≥90% DNL inhibition)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PF-05221304 (steady-state pharmacokinetics)
Number of subjects: 96
Study: 35333207

Group type: EXPERIMENTAL
Intervention: Tranexamic acid microinjection
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 29
Study: 32286132

Group type: EXPERIMENTAL
Intervention: HMD‐VR
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional computer monitor
Number of subjects: 40
Study: 33623830

Group type: EXPERIMENTAL
Intervention: Anti-adhesion gel
Number of subjects: 444

Group type: COMPARATOR
Intervention: No gel (control group)
Number of subjects: 444
Study: 32513069

Group type: EXPERIMENTAL
Intervention: Naringin 450 mg every 24 hours for 90 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 33410265

Group type: EXPERIMENTAL
Intervention: 5% sofpironium bromide (BBI-4000) gel
Number of subjects: 281

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 281
Study: 32677999

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HST) with post-test phone counseling and referral (eTest condition)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HST) without active follow-up (standard condition)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Reminders to get tested for HIV at a local clinic (control)
Number of subjects: 900
Study: 35361724

Group type: EXPERIMENTAL
Intervention: Roxadustat (oral, three times weekly)
Number of subjects: 2133

Group type: COMPARATOR
Intervention: Epoetin alfa (parenteral, per local clinic practice)
Number of subjects: 2133

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 2133

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 2133
Study: 34622680

Group type: COMPARATOR
Intervention: Low-volume centers (n=537)
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Intermediate-volume centers (n=240)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: High-volume centers (n=255)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: All volume categories
Number of subjects: 1032
Study: 33608398

Group type: EXPERIMENTAL
Intervention: Early continuous renal replacement therapy (CRRT) initiated immediately after randomisation
Number of subjects: 460

Group type: COMPARATOR
Intervention: Delayed continuous renal replacement therapy (CRRT) initiated based on specific criteria (stage 3 KDIGO, severe hyperkalaemia, pulmonary oedema, blood urea nitrogen > 112 mg/dL)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Early CRRT
Number of subjects: 460

Group type: COMPARATOR
Intervention: Delayed CRRT
Number of subjects: 460
Study: 32844606

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) for 20 minutes in upright position, 2 hours postprandial.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received no intervention, placed in the same position for 20 minutes, 2 hours postprandial.
Number of subjects: 100
Study: 35902953

Group type: EXPERIMENTAL
Intervention: HMD‐VRC group
Number of subjects: 30

Group type: COMPARATOR
Intervention: RP group
Number of subjects: 30